Funabashi, Japan

Kotatsu Matsubara

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Nissan Chemical Industries Limited. Active years: 2015.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Kotatsu Matsubara

Introduction

Kotatsu Matsubara is a notable inventor based in Funabashi, Japan. He has made significant contributions to the field of chemistry, particularly in the development of crystalline polymorphs. His work has implications for various applications in the pharmaceutical industry.

Latest Patents

Matsubara holds a patent for "Crystalline polymorphs of isoxazoline compound and production method thereof." This patent details a method for manufacturing a crystal of (S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide. The patent elucidates the existence of a crystalline polymorph of this compound and outlines the method for its production.

Career Highlights

Matsubara is currently employed at Nissan Chemical Industries Limited, where he continues to innovate and contribute to the field. His work at the company has allowed him to explore new chemical compounds and their potential applications.

Collaborations

Throughout his career, Matsubara has collaborated with esteemed colleagues such as Hotaka Imanaka and Takeshi Mita. These collaborations have fostered a productive environment for research and development.

Conclusion

Kotatsu Matsubara's contributions to the field of chemistry, particularly through his patent on crystalline polymorphs, highlight his innovative spirit and dedication to advancing scientific knowledge. His work at Nissan Chemical Industries Limited continues to pave the way for future discoveries.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…